The evolution of the class of antibacterial quinolones includes the introduction in therapy of
highly successful compounds. Although many representatives were withdrawn due to …

Ophthalmic disease can cause permanent loss of vision and blindness. Easy-to-administer
topical and systemic treatments are preferred for treating sight-threatening disorders. Typical …

Uveitis is a sight-threatening disease that causes inflammation in the uvea; difluprednate
(DFB) is the first approved drug molecule for postoperative pain, inflammation, and …

In this study, moxifloxacin (MX)-loaded bilosome (BS) in situ gel was prepared to improve
ocular residence time. MX-BSs were prepared using the thin-film hydration method. They …

Recent years have witnessed a boom in ocular nanomedicine research with a number of
lipid-based nanocarriers such as liposomes, niosomes, cubosomes, nanoemulsions, solid …

Introduction Retinal diseases are one of the main reasons for vision loss where all available
drug treatments are based on invasive drug administration such as intravitreal injections …

Effective drug delivery to intraocular tissues remains a great challenge due to complex
anatomical and physiological barriers that selectively limit the entry of drugs into the eye. To …

Ocular disorders can lead to serious sight impairment and irreversible blindness. Generally
simple topical and systemic treatments are recommended for treating these vision …

Conventional eye drops are most commonly employed topically in the eye for the
management of bacterial conjunctivitis. Eye drops have a low corneal residence time and 90 …

Isoliquiritigenin (ISL), as a natural flavonoid, has been proven to have therapeutic potential
for corneal neovascularization (CNV) treatment; however, its therapeutic use is restricted …